

Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQB: LVCLY

03 May 2023

Living Cell Technologies Limited
Level 23, Rialto South Tower
525 Collins Street
Melbourne, Victoria 3000
AUSTRALIA
Ph: +61 422 180 317
Email: brad@lctglobal.com
Web: www.lctglobal.com
ABN: 14 104 028 042

Completion of Entitlement Offer Shortfall

Melbourne, Australia and Auckland, New Zealand – Living Cell Technologies Ltd (“LCT” or “the Company”) is pleased to announce that the Entitlement Offer Shortfall, which totalled \$693,972.89, has been allocated to investors by Alignment Capital Pty Ltd (“Alignment”), pursuant to the capital raising agreement announced to ASX on February 01, 2023.

As described in the Quarterly Report for the period ending 31 March 2023, LCT has budgeted a substantial proportion of new capital raised be allocated to the assessment and commencement of additional projects to expand the Company’s development pipeline. LCT has multiple projects under scientific and commercial assessment and has entered discussions with contract research organisations and academic institutions to assist in the advancement of new project assessments.

Authorised for release by the Board of Living Cell Technologies Limited.

Ends

For further information: www.lctglobal.com

Corporate and Media Enquiries

Brad Dilkes
Non-executive Director
Mobile: +61 422 180 317
brad@lctglobal.com